CannTrust Holdings Inc
Top Developments in the Cannabis Industry’s Early Years
In the second half of 2018, the cannabis industry remained busy. As the cannabis sector experienced a boom, there was a lot of excitement among investors.
Could Leon Cooperman Gain from Cannabis Legalization Moves?
As CNBC reported yesterday, New Jersey legislators unveiled a plan to legalize cannabis (CGC) for adults in the state.
What Investors Are Paying for CRON, HEXO, TRST, and Others
OrganiGram, Supreme Cannabis, and HEXO were trading at a discount to the peer median of 6.8x as of February 22.
Gundlach Compares Cannabis to Bitcoin
Jeffrey Gundlach predicted bitcoin’s (BTC) crash after the cryptocurrency’s peak in December 2017.
What Analysts Expect from Trulieve’s Revenue in 2018 and 2019
On January 14, 2019, Trulieve opened its 24th dispensary in Florida in St. John’s County.
What Analysts Recommend for CannTrust in February
In February, analysts’ consensus recommendation for CannTrust was a “buy.”
Why CannTrust Is Trending Higher in February
CannTrust (CNTTF) has returned nearly 75% year-to-date.
EV-to-Sales Valuation Multiple: CRON, HEXO, and Others
Cronos Group was trading at a forward multiple of 39.9x, which increased from 30.3x on January 18.
A Look at Curaleaf’s Core Operations and Expansion Plans
Curaleaf Holdings (CURA) (CURLF) is a vertically integrated cannabis company headquartered in Wakefield, Massachusetts.
How Altria Aims to Accelerate Cronos Group’s Growth
Altria’s (MO) experience in the tobacco business could be leveraged to accelerate penetration in the marijuana market.
Canopy Growth’s Bruce Linton Talks Next Steps for the Industry
Last week, Canopy Growth CEO Bruce Linton shed light on the next phases for the cannabis industry at the Cantech Investment Conference.
Kamala Harris: Presidential Candidate for Legalizing Marijuana
Senator Kamala Harris, who also announced her 2020 presidential bid, supports legalizing marijuana at a federal level.
Premium on Aphria Vanished, No More ‘Failed Investment’
With Aphria slightly higher than Green Growth’s offer, the selling point of a 45% premium has vanished.
CannTrust Holdings’ Stock Grew ~11% Last Week
On January 25, CannTrust Holdings’ (CNTTF) stock price closed at $6.87, ~5.19% higher than its closing price of $6.53 on January 24 and ~11% higher than its closing price of $6.21 on January 18.
A Look at iAnthus Capital’s Strategic Partnerships
In the third quarter of 2018, which ended on September 30, iAnthus Capital posted revenue of $1.07 million, which represents an increase of 101% from $0.53 million in the second quarter of 2018.
Latest Offer: Aphria Urges Investors to ‘Take No Action’
Aphria urged its shareholders to “take no action” on Green Growth’s offer until the board “has made a formal recommendation to shareholders.”
How Analysts Rate CRON, APHA, and CNTTF in January
Cronos Group has gained nearly 33% YTD as of January 22.
What the Valuations of CRON, HEXO, and CNTTF Indicate This Month
OrganiGram Holdings (OGRMF), CannTrust (CNTTF), and Supreme Cannabis (SPRWF) are all trading at discounts to the industry median at 9.9x, 14.4x, and 9.6x, respectively.
Valuations of CRON, HEXO, and Others : Which Stocks Look Cheap?
In this article, we’ll look at the other five stocks that make up the cannabis industry’s median multiple.
Big Headlines that Drove Cannabis Stocks Yesterday
Yesterday, Tilray announced a revenue sharing agreement with ABG (Authentic Brands Group).
How Hemp License Sets CGC on a Path to a Billion Dollars in Sales
In its recent earnings call, Constellation Brands shed some light on Canopy Growth’s sales.
CannTrust Holdings: Analysts Are Mainly Positive in January
On January 8, CannTrust Holdings’ (CNTTF) stock price closed at $5.63, which is ~3.04% growth from its close of $5.47 on January 7.
Medical Cannabis Business Could Be a Huge Windfall for Investors
While recreational cannabis has gained publicity, the medical cannabis business could lead to a huge windfall for investors.
Why Tilray Had a Stellar 2018
In September, the US government approved Tilray’s cannabis drug for import for use in clinical trials assessing relief to patients with essential tremors.
Cronos Group’s Valuation Multiple Rose in December
Cronos Group’s (CRON) forward EV-to-sales multiple in December rose to 19.9x from 19.7x on November 30.
How CannTrust Is Targeting Asia-Pacific and German Markets
On October 28, CannTrust Holdings (CNTTF) announced a strategic partnership with Australian cannabis producer, Cannatrek.
CannTrust’s Earnings Are Expected to Grow Rapidly
In the first nine months of this year, CannTrust Holdings’ (CNTTF) adjusted EBITDA fell 66.79% YoY (year-over-year) to 1.17 million Canadian dollars, and its net income rose 1,793.06% YoY to 11.97 million Canadian dollars.
Valuations: Cannabis Companies Got Battered
CannTrust, Supreme Cannabis, HEXO, and Aphria were trading at a discount to their levels in November. Cannabis stocks have gotten cheaper.
Are Cannabis Stocks Trading Cheap?
OrganiGram (OGRMF) was trading right at the median at a forward EV-to-sales multiple of 4.6x.
What Analysts Recommend for CannTrust
CannTrust (CNTTF) reported its earnings last week on November 14.
Most Cannabis Companies Expected to Report Losses for the Quarter
Aurora Cannabis is estimated to report a loss per share of 0.07 Canadian dollars, which would be lower than the profit per share of 0.01 Canadian dollars in the corresponding quarter in 2017.
Cannabis Companies Are Expected to Report Healthy Gross Margins
Cannabis companies (HMMJ) are expected to report impressive YoY revenue growth in the most recent quarter.
Organigram’s Consensus Price Target Rose in August
Organigram (OGRMF) is among the top gainers compared to cannabis companies (HMMJ) such as Canopy Growth (WEED) (CGC) and Hydropothecary (HYYDF).
Cannabis Stocks Took a Nosedive Last Week
Last week, the cannabis sector slipped into negative territory. The Horizons Marijuana Life Sciences ETF (HMMJ) fell about 8.8%.
March Analyst Ratings and Price Targets for Aphria
Aphria (APHQF) was among the worst performers this year with a loss of 34% YTD (year-to-date).
How Analysts’ Price Target and Ratings for Cronos Group Changed in March
As of March 22, the consensus analyst mean rating on Cronos Group was 2.3, which remained unchanged from the previous month.